Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19

[June 24, 2020]  (Reuters) - Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in high-risk hospitalized adults tested positive for COVID-19.

The company expects to report topline data in the first quarter of 2021.

Fulcrum said it had exclusively in-licensed losmapimod from GlaxoSmithKline PLC last year.

(Reporting By Mrinalika Roy in Bengaluru, Editing by Sherry Jacob-Phillips)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.